Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Biotechnology

Healthcare
$2.11 +1.84%

+$0.06 today

Market cap
$235.60M
Beta
0.47
P/E (TTM)
-1.7
EPS (TTM)
-$1.87
52W Low $2.40High $5.45

Volume 2.49M

Average 3.15M

RCKT Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Rocket Pharmaceuticals, Inc.NASDAQ: RCKT

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures declines year over year

Q1 FY2026 capital expenditures of $93K (cash outflow) fell 74.5% year over year, ahead of the -96.0% change in trailing-twelve-month capital expenditures. Sequentially, it rose 16.3% from the prior quarter. Over 3 fiscal years it compounded at -62.9% a year.

Context

  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -74.5% holds above the trailing-twelve-month pace of -96.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$93K+16.3% QoQ
Last fiscal yearDec 2025
-$440K-92.5% YoY
LTMMar 2026
-$169K-96.0% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-74.5%——
1 year-92.5%——
3-year CAGR-62.9%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(440K) USD
Year-over-year change
+92.5%

Capital Expenditures vs competitors

How RCKT compares with its peers on the latest reported figures

  • RCKT's LTM Mar 2026 capital expenditures of $169K is the 6th largest of the 10 companies compared; the peer median is $362K.
  • Its year-over-year change of -96.0% is the lowest of 8, against a peer median of -44.2%.
  • Over three fiscal years its annual growth of -62.9% compares with a peer median of -27.4%.
RCKT Competitors Peer median
Capital Expenditures for RCKT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AUTLAutolus Therapeutics plcLTM Mar 2026$18.2M -57.2%+35.8%19.7%
QSIQuantum-Si incorporatedLTM Mar 2026$1.49M -69.3%-38.3%80.4%
SLDBSolid Biosciences Inc.LTM Mar 2026$1.19M +88.9%-27.4%—
DBVTDBV Technologies S.A.LTM Mar 2026$928K -8.4%-10.9%—
AURAAura Biosciences, Inc.LTM Mar 2026$362K -73.2%-25.8%—
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$169K -96.0%-62.9%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$121K -44.2%-40.5%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$78K ———
ANNXAnnexon, Inc.LTM Mar 2026$63K -29.2%-72.4%—
GALTGalectin Therapeutics Inc.LTM Mar 2026$0 ———
Peer median (excluding RCKT) $362K-44.2%-27.4%50.0%

Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(169.07M)(221.86M)(245.6M)(258.75M)(223.12M)
Depreciation & Amortization5.37M6.27M7.1M9.38M11.03M
Deferred Income Tax3.15M0000
Stock-Based Compensation29.24M31.01M39.41M43.92M37.06M
Change in Working Capital(3.39M)6.08M13.46M1.92M(8.3M)
Accounts Receivables00000
Inventory00000
Accounts Payables(4.83M)9.67M000
Other Working Capital1.44M(3.6M)13.46M1.92M(8.3M)
Other Non-Cash Items13.53M370K(9.28M)(6.19M)(6.68M)
Operating Cash Flow(121.16M)(178.14M)(194.92M)(209.72M)(190.01M)
Capital Expenditures(7.72M)(8.62M)(16.47M)(5.86M)(440K)
Acquisitions (Net)95K42.73M000
Purchases of Investments(245.88M)(376.33M)(390.92M)(245.89M)(276.55M)
Sales of Investments272.44M272.89M309.33M383.45M380.76M
Other Investing Activities(95K)0000
Investing Cash Flow18.85M(69.33M)(98.07M)131.71M103.77M
Debt Repayment201K172K139K00
Common Stock Issued37.68M155.34M208.39M185.74M0
Common Stock Repurchased0(47K)00(67K)
Dividends Paid00000
Other Financing Activities(201K)(172K)(132K)0215K
Financing Cash Flow37.68M155.29M208.4M185.74M148K
Effect of Forex Changes00000
Net Change in Cash(64.63M)(92.18M)(84.58M)107.72M(86.1M)
Free Cash Flow(128.88M)(186.76M)(211.39M)(215.59M)(190.45M)

Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Intrinsic Alpha fair value

Locked

Current Price

$2.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.